John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cisco
CSCO
|
+$226M |
| 2 |
JPMorgan Chase
JPM
|
+$212M |
| 3 |
TSMC
TSM
|
+$204M |
| 4 |
Occidental Petroleum
OXY
|
+$194M |
| 5 |
Apple
AAPL
|
+$180M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$271M |
| 2 |
Microsoft
MSFT
|
+$267M |
| 3 |
Canadian Pacific Kansas City
CP
|
+$255M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$226M |
| 5 |
Coca-Cola
KO
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.48% |
| 2 | Healthcare | 15.21% |
| 3 | Industrials | 10.23% |
| 4 | Consumer Discretionary | 10.15% |
| 5 | Financials | 9.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALPN
2076
DELISTED
Alpine Immune Sciences Inc
ALPN
| $428K | ﹤0.01% |
47,708
-31,974
| -40% | -$276K |
|
2077
NetApp
NTAP
$36.8B
| $427K | ﹤0.01% |
5,148
-62,708
| -92% | -$5.45M |
|
|
BBBY
2078
DELISTED
Bed Bath & Beyond Inc
BBBY
| $425K | ﹤0.01% |
18,875
-712,894
| -97% | -$12.4M |
|
2079
Mid Penn Bancorp
MPB
$937M
| $424K | ﹤0.01% |
15,822
-1,616
| -9% | -$46.9K |
|
|
MKFG
2080
DELISTED
Markforged Holding Corporation
MKFG
| $423K | ﹤0.01% |
10,605
-5,220
| -33% | -$228K |
|
|
SUP
2081
DELISTED
Superior Industries International
SUP
| $422K | ﹤0.01% |
90,634
-79,339
| -47% | -$347K |
|
2082
Outlook Therapeutics
OTLK
$155M
| $420K | ﹤0.01% |
11,806
-26,701
| -69% | -$834K |
|
2083
Capital Bancorp
CBNK
$592M
| $419K | ﹤0.01% |
18,349
+3,298
| +22% | +$80.9K |
|
|
GNFT
2084
DELISTED
Genfit
GNFT
| $419K | ﹤0.01% |
104,625
+18,253
| +21% | +$74.6K |
|
2085
Zedge
ZDGE
$38.4M
| $419K | ﹤0.01% |
68,752
+23,541
| +52% | +$166K |
|
|
AFCG
2086
AFC Gamma
AFCG
$76.9M
| $415K | ﹤0.01% |
31,715
+16,832
| +113% | +$227K |
|
2087
Alkami Technology
ALKT
$2.15B
| $412K | ﹤0.01% |
28,825
+17,925
| +164% | +$274K |
|
|
PVLA
2088
Palvella Therapeutics
PVLA
$2.14B
| $412K | ﹤0.01% |
1,698
-11,150
| -87% | -$2.93M |
|
2089
Atomera
ATOM
$178M
| $411K | ﹤0.01% |
+31,439
| New | +$471K |
|
|
LRFC
2090
DELISTED
Logan Ridge Finance Corp
LRFC
| $409K | ﹤0.01% |
18,115
-6,000
| -25% | -$147K |
|
2091
Arcutis Biotherapeutics
ARQT
$3.12B
| $408K | ﹤0.01% |
+21,192
| New | +$359K |
|
2092
Limoneira
LMNR
$250M
| $408K | ﹤0.01% |
27,798
+4,654
| +20% | +$67.7K |
|
|
GTH
2093
DELISTED
Genetron Holdings Limited ADS
GTH
| $408K | ﹤0.01% |
62,041
-40,257
| -39% | -$441K |
|
2094
Genesco
GCO
$374M
| $407K | ﹤0.01% |
+6,400
| New | +$416K |
|
2095
Universal Insurance Holdings
UVE
$1.2B
| $407K | ﹤0.01% |
30,199
-50,618
| -63% | -$759K |
|
|
LBC
2096
DELISTED
Luther Burbank Corporation Common Stock
LBC
| $407K | ﹤0.01% |
30,590
-5,646
| -16% | -$75.7K |
|
2097
GATX Corp
GATX
$6.33B
| $403K | ﹤0.01% |
3,271
-9,204
| -74% | -$1.01M |
|
2098
MediaAlpha
MAX
$787M
| $402K | ﹤0.01% |
24,276
-42,326
| -64% | -$592K |
|
|
PVBC
2099
DELISTED
Provident Bancorp
PVBC
| $402K | ﹤0.01% |
24,800
-3,844
| -13% | -$65.3K |
|
2100
Acacia Research
ACTG
$439M
| $400K | ﹤0.01% |
88,587
+661
| +0.8% | +$2.78K |
|
Similar funds
John Overdeck's Q1 2022 Portfolio in Review
As of Q1 2022, John Overdeck held 4,846 positions worth $33.9B, down 28% from $46.8B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
John Overdeck withdrew a net $11.3B in Q1 2022, closing 2,304 positions and reducing 976 holdings. Its most notable exit was Pfizer, an estimated $271M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, John Overdeck opened a new position in Cisco worth $223M.
- John Overdeck's largest Q1 2022 buy was Cisco: 4,001,362 shares worth $223M.
- John Overdeck added most to JPMorgan Chase in Q1 2022, an estimated $212M increase.
- John Overdeck's biggest Q1 2022 reduction was Coca-Cola, cutting an estimated $225M.
- John Overdeck fully exited Pfizer in Q1 2022, selling an estimated $271M.
- John Overdeck's ten largest holdings make up 7.2% of its $33.9B portfolio in Q1 2022.
- John Overdeck opened 656 new positions and closed 2,304 in Q1 2022.
- John Overdeck's portfolio value fell 28% quarter-over-quarter to $33.9B.
Based on Two Sigma Investments's 13F filing for Q1 2022, filed 16 May 2022.